$12.31
0.16% yesterday
Nasdaq, Aug 11, 10:01 pm CET

10x Genomics Inc - Ordinary Shares - Class A Stock price

$12.31
-0.49 3.83% 1M
+0.49 4.15% 6M
-2.05 14.28% YTD
-7.34 37.35% 1Y
-36.01 74.52% 3Y
-84.59 87.30% 5Y
-40.44 76.66% 10Y
-40.44 76.66% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+0.02 0.16%

Key metrics

Basic
Market capitalization
$1.5b
Enterprise Value
$1.1b
Net debt
positive
Cash
$426.9m
Shares outstanding
123.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
2.4 | 2.5
EV/Sales
1.7 | 1.8
EV/FCF
24.0
P/B
2.1
Financial Health
Equity Ratio
77.3%
Return on Equity
-25.7%
ROCE
-22.8%
ROIC
-44.4%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$624.7m | $594.0m
EBITDA
$-137.3m | $-134.9m
EBIT
$-181.6m | $-160.9m
Net Income
$-157.0m | $-150.3m
Free Cash Flow
$44.4m
Growth (TTM | estimate)
Revenue
-0.1% | -2.8%
EBITDA
33.2% | 9.3%
EBIT
25.5% | 16.4%
Net Income
40.6% | 17.7%
Free Cash Flow
160.0%
Margin (TTM | estimate)
Gross
68.4%
EBITDA
-22.0% | -22.7%
EBIT
-29.1%
Net
-25.1% | -25.3%
Free Cash Flow
7.1%
More
EPS
$-1.3
FCF per Share
$0.4
Short interest
19.2%
Employees
1k
Rev per Employee
$470.0k
Show more

Is 10x Genomics Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

10x Genomics Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

22 Analysts have issued a 10x Genomics Inc - Ordinary Shares - Class A forecast:

10x Buy
45%
12x Hold
55%

Analyst Opinions

22 Analysts have issued a 10x Genomics Inc - Ordinary Shares - Class A forecast:

Buy
45%
Hold
55%

Financial data from 10x Genomics Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
625 625
0% 0%
100%
- Direct Costs 198 198
11% 11%
32%
427 427
6% 6%
68%
- Selling and Administrative Expenses 348 348
3% 3%
56%
- Research and Development Expense 260 260
16% 16%
42%
-137 -137
33% 33%
-22%
- Depreciation and Amortization 44 44
16% 16%
7%
EBIT (Operating Income) EBIT -182 -182
26% 26%
-29%
Net Profit -157 -157
41% 41%
-25%

In millions USD.

Don't miss a Thing! We will send you all news about 10x Genomics Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

10x Genomics Inc - Ordinary Shares - Class A Stock News

Neutral
Seeking Alpha
3 days ago
10x Genomics, Inc. (NASDAQ:TXG ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Adam S. Taich - CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer Cassie Corneau - Manager of Investor Relations & Strategic Finance Serge Saxonov - Co-Founder, CEO & Director Conference Call Participants Daniel Anthony Arias - Stifel, Nicolaus & Company, Inc...
Neutral
PRNewsWire
4 days ago
PLEASANTON, Calif. , Aug. 7, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2025.
Neutral
PRNewsWire
4 days ago
Acquisition Will Further Expand Chromium's Capabilities PLEASANTON, Calif. , Aug. 7, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it has signed a definitive agreement to acquire Scale Biosciences, Inc., a leader in innovative and scalable single cell analysis.
More 10x Genomics Inc - Ordinary Shares - Class A News

Company Profile

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company's products include Single Cell Gene Expression, Immune Profiling, CNV, ATAC, and Genome and Exome. 10X Genomics was founded by Serge Saxonov, Ben Hindson, Kevin D. Ness and Eduard Diviu Terradas on July 2, 2012 and is headquartered in Pleasanton, CA.

Head office United States
CEO Serge Saxonov
Employees 1,306
Founded 2012
Website www.10xgenomics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today